Sign In
Buy CVAC
$4.66
+0 (+0%)
At Close: Apr 02, 2026
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
08:15am, Wednesday, 01'st Nov 2023
COVID-19 Phase 2 clinical trial fully enrolled Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine First participant dosed in seasonal flu Phase 2 part of
Why CureVac Stock Plunged Today
09:07am, Friday, 29'th Sep 2023
CureVac previously failed to develop a successful COVID-19 vaccine, but filed a lawsuit last year against BioNTech alleging intellectual property violations. On Thursday a German court paused proceedi
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
07:15am, Thursday, 28'th Sep 2023
Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTech Ruling on infringement to be provided latest once the validit
CureVac signals progress on mRNA flu vaccine
08:05am, Tuesday, 12'th Sep 2023
CureVac NV CVAC, -3.85% said Tuesday that it has selected an mRNA flu vaccine candidate for continued clinical development, based on positive results from an early-stage study conducted in collaborati
Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mRNA constructs per candidate Best-performing candidate providing broad
3 Stocks to Buy For the COVID Resurgence
08:44am, Thursday, 07'th Sep 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting
Why Shares of CureVac Jumped This Week
12:35pm, Friday, 23'rd Jun 2023
CureVac has an ongoing collaboration with GlaxoSmithKline. It just launched the first clinical study of a vaccine using CureVac's next-generation mRNA platform.
Why CureVac Stock Leaped 12% Higher Today
06:29pm, Tuesday, 20'th Jun 2023
The European biotech delivered some promising news from the laboratory. It has dosed its first patient in a crucial phase 1 trial of its cancer vaccine.
Peter Kolchinsky-led RA Capital's New Positions Feature CureVac, Mineralys, Pilant, Enliven Therapeu
10:32pm, Tuesday, 23'rd May 2023
The Boston-based fund has emerged as a force to be reckoned with in the world of biotech investments.
CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
08:26am, Friday, 19'th May 2023
CureVac NV said on Friday it had filed an expanded patent infringement claim against Pfizer Inc and BioNTech over the use of mRNA technology and that a U.S. court had granted its request to transfer t
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
07:30am, Tuesday, 18'th Apr 2023
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2023 / CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucl
UBS: CureVac has a ‘potentially competitive mRNA platform'
01:56pm, Thursday, 19'th Jan 2023
CureVac's CVAC, +8.44% promising Phase 1 data for flu and COVID-19 vaccine candidates is a signal to investors that its messenger RNA technology is, in fact, competitive, according to UBS Securities a
UBS reveals a biotech stock that can nearly double from here
01:06pm, Thursday, 19'th Jan 2023
Shares of CureVac BV (NASDAQ: CVAC) have already almost doubled year-to-date but a UBS analyst says the stock still has a lot more room to the upside.
7 Biotech Stocks That Will Make You Rich in 10 Years
03:44pm, Wednesday, 18'th Jan 2023
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they'r
Why CureVac's Shares Jumped on Tuesday
04:16pm, Tuesday, 10'th Jan 2023
The stock rose for the third consecutive day.
